Elecsys EBV EBNA IgG
Epstein-Barr Virus, Other. 510(k) K260221, from Roche Diagnostics (Indianapolis, IN). Product code LSE, class 1.
As of Nov 21, 2026, K260221 is an FDA 510(k) held by Roche Diagnostics, substantially equivalent on Oct 2, 2026 after 249 days, with no recalls tied to it in FDA's recall database.
- Review time: 249 days
- Recalls: 0
Immunoassay for the in vitro qualitative detection of IgG antibodies to Epstein-Barr virus Nuclear Antigen-1 (EBNA-1) in human serum and plasma. When performed in conjunction with other Epstein-Barr virus markers, this assay is intended for use as an aid in the diagnosis of Epstein-Barr virus infection, such as infectious mononucleosis.
- Elecsys EBV VCA IgGK260232 · Roche Diagnostics · Oct 2, 2026
- ADVIA Centaur EBV-VCA IgMK233606 · Biokit, S.A. · Aug 7, 2024
- Document
- 510(k) summary (PDF) ↗
- Type
- Traditional
- Received
- Jan 26, 2026
- Review panel
- Microbiology
- Regulation
- 21 CFR 866.3235
One page per 510(k), De Novo and original PMA. Recalls are those FDA's recall database ties to this number; recalls of related devices that cite another number are not shown. Refreshed weekly. Predicates are read by Arca from the text of FDA's 510(k) summary PDFs, most of them scans: a device number counts when the summary names it as a predicate or as the device it is substantially equivalent to. About 97% of those read were right on a sample we checked by hand; summaries from before 2000 often name predicates without a number, so older devices show fewer. Pivotal studies are read by a model from FDA's De Novo decision summaries and PMA SSEDs; a count or result is shown only when its numbers appear in FDA's text. openFDA device 510(k), PMA and recall files